Why the study?
Tricuspid regurgitation is a prevalent cardiovascular disease that necessitates innovative, less invasive treatments.
Transcatheter tricuspid valve interventions, including edge-to-edge repair, replacement, and direct annuloplasty, are emerging as safe and effective less invasive therapies for tricuspid regurgitation.
Caution against routine adoption for tricuspid regurgitation; leaves open their role pending randomized trials.
Tricuspid regurgitation (TR) is a prevalent cardiovascular disease necessitating innovative treatments. Assessing comorbidities, such as right ventricular dysfunction, is pivotal for the therapeutic strategy. Preprocedural echocardiographic assessments are crucial for achieving optimal TR reduction. Transcatheter interventions have emerged as less invasive therapies. Tricuspid transcatheter edge-to-edge repair is the predominant technology, proven safe and effective in reducing TR. Additionally, transcatheter tricuspid valve replacement and direct annuloplasty technologies have been developed and recognized as attractive alternatives, each with unique advantages. This review discusses the innovation, current landscape, and future perspective of transcatheter tricuspid valve interventions for treating TR.
No takes yet. Share an insight, caveat, or question.
Sugiura et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: